EMA com­mit­tee rec­om­mends Al­ny­lam's ear­ly-stage AT­TR amy­loi­do­sis drug for or­phan sta­tus

With the spot­light on patisir­an’s like­ly im­mi­nent ap­proval, Al­ny­lam $AL­NY wants to show some love for its fol­low-on drug for transthyretin-me­di­at­ed (AT­TR) amy­loi­do­sis, which is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER